The National Institute for Health and Care Excellence (NICE) has officially endorsed Etrasimod, under the trade name Velsipity by Pfizer, for individuals aged 16 and older suffering from moderately to severely active ulcerative colitis. This recommendation comes after evaluating the drug’s effectiveness and cost, highlighting its suitability for patients who have not seen adequate responses or cannot tolerate conventional or biological treatments.
Etrasimod stands out for its promising clinical trial results, making it a competitive option against other advanced treatments while offering a cost-effective solution due to a confidential commercial arrangement with the NHS. This guidance mandates that NHS England and integrated care boards ensure Etrasimod’s availability within a specified timeframe, underscoring its significance as a valuable treatment alternative for eligible patients.
NICE Recommends Etrasimod: A Cost-Effective Ulcerative Colitis Therapy with NHS Support
The advice emphasizes Etrasimod’s use based on a commercial arrangement and encourages selecting the least expensive option after considering various treatments. Etrasimod, a sphingosine-1-phosphate receptor agonist, shows promise based on clinical trials and cost-effectiveness, positioning it as a valuable option alongside existing treatments.
It’s marked for those who haven’t responded well to conventional therapies or biological agents, with specifics on dosage and pricing provided, alongside a commercial arrangement offering NHS discounts. Implementation guidelines require NHS compliance within set timeframes, ensuring Etrasimod’s availability for suitable patients as per NICE’s recommendations.
Resource: NICE, March 11, 2024
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
